Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
P78330

UPID:
SERB_HUMAN

ALTERNATIVE NAMES:
L-3-phosphoserine phosphatase; O-phosphoserine phosphohydrolase

ALTERNATIVE UPACC:
P78330; B2RCR5; Q7Z3S5

BACKGROUND:
The enzyme Phosphoserine phosphatase, with alternative names L-3-phosphoserine phosphatase and O-phosphoserine phosphohydrolase, is essential for L-serine biosynthesis from carbohydrates. It facilitates the last irreversible step by dephosphorylating O-phospho-L-serine to L-serine. L-serine's significance extends to protein synthesis, other amino acids production, nucleotide metabolism, glutathione synthesis, and as a precursor to the neuromodulator D-serine.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Phosphoserine phosphatase could open doors to potential therapeutic strategies for addressing its deficiency, which manifests in growth retardation and moderate psychomotor retardation, akin to Williams syndrome. The enzyme's critical function in metabolic pathways presents a promising target for novel treatments.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.